These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23059147)

  • 41. Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism.
    Dorado P; González I; Naranjo ME; de Andrés F; Peñas-Lledó EM; Calzadilla LR; LLerena A
    OMICS; 2017 Jan; 21(1):17-26. PubMed ID: 28271978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overview of pharmacological approaches to therapy for Tourette syndrome.
    van Woert MH; Rosenbaum D; Enna SJ
    Adv Neurol; 1982; 35():369-75. PubMed ID: 6183950
    [No Abstract]   [Full Text] [Related]  

  • 43. Personalized medicine into the next generation.
    Ingelman-Sundberg M
    J Intern Med; 2015 Feb; 277(2):152-154. PubMed ID: 25354249
    [No Abstract]   [Full Text] [Related]  

  • 44. Cytochrome P450 2D6 polymorphism and character traits.
    Suzuki E; Kitao Y; Ono Y; Iijima Y; Inada T
    Psychiatr Genet; 2003 Jun; 13(2):111-3. PubMed ID: 12782969
    [TBL] [Abstract][Full Text] [Related]  

  • 45. More on Tourette syndrome and school phobia.
    Am J Psychiatry; 1986 Feb; 143(2):265-6. PubMed ID: 2868668
    [No Abstract]   [Full Text] [Related]  

  • 46. The role of pimozide in clinical psychiatry: a review.
    Opler LA; Feinberg SS
    J Clin Psychiatry; 1991 May; 52(5):221-33. PubMed ID: 2033030
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Gilles de la Tourette-syndrome: treatment of a neuropsychiatric disorder].
    Kawohl W
    Praxis (Bern 1994); 2010 Nov; 99(22):1353-60. PubMed ID: 21049442
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Tourette syndrome. New aspects on pharmacological treatment].
    Aabech HS
    Tidsskr Nor Laegeforen; 1989 Mar; 109(9):961-3. PubMed ID: 2565050
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder.
    Sallee FR; Nesbitt L; Jackson C; Sine L; Sethuraman G
    Am J Psychiatry; 1997 Aug; 154(8):1057-62. PubMed ID: 9247389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CYP2D6 testing for breast cancer patients: is there more to the story?
    Henry NL; Hayes DF; Rae JM
    Oncology (Williston Park); 2009 Dec; 23(14):1236, 1243, 1249. PubMed ID: 20120836
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of genetic polymorphism on the inhibition of dopamine formation from p-tyramine catalyzed by brain cytochrome P450 2D6.
    Niwa T; Shizuku M; Yamano K
    Arch Biochem Biophys; 2017 Apr; 620():23-27. PubMed ID: 28347660
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
    He ZX; Chen XW; Zhou ZW; Zhou SF
    Drug Metab Rev; 2015; 47(4):470-519. PubMed ID: 26574146
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome.
    Steeves TD; Fox SH
    Prog Brain Res; 2008; 172():495-513. PubMed ID: 18772048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
    Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
    Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Diagnosis and treatment recommendations for tic disorders in children].
    Subspecialty Group of Neurology, The Society of Pediatrics, Chinese Medical Association
    Zhonghua Er Ke Za Zhi; 2013 Jan; 51(1):72-5. PubMed ID: 23527937
    [No Abstract]   [Full Text] [Related]  

  • 56. Tamoxifen, endoxifen, and CYP2D6: the rules for evaluating a predictive factor.
    Goetz MP
    Oncology (Williston Park); 2009 Dec; 23(14):1233-4, 1236. PubMed ID: 20120835
    [No Abstract]   [Full Text] [Related]  

  • 57. Personalized medicine: the impact on chemistry.
    Watkins J; Marsh A; Taylor PC; Singer DR
    Ther Deliv; 2010 Nov; 1(5):651-65. PubMed ID: 22833955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tourette syndrome: gene expression as a tool to discover drug targets.
    Liao IH; Sharp FR
    Neurotherapeutics; 2010 Jul; 7(3):302-6. PubMed ID: 20643383
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioimmunoassay of pimozide.
    Michiels M; Hendriks R; Heykants J
    Methods Enzymol; 1982; 84():542-51. PubMed ID: 7098966
    [No Abstract]   [Full Text] [Related]  

  • 60. Advancing precision medicine for the treatment of long-QT syndrome type 2: shedding light on lumacaftor.
    Delisle BP; January CT
    Eur Heart J; 2018 Apr; 39(16):1456-1458. PubMed ID: 29040441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.